Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium

Clinical and Translational Science, Journal Year: 2025, Volume and Issue: 18(3)

Published: March 1, 2025

ABSTRACT The use of a liquid biopsy to assess molecular residual disease (MRD) solid tumors holds significant promise for improving outcomes patients with cancer. Liquid biopsies are minimally invasive approach the identification circulating tumor biomarkers through simple blood sample. Assays capable detecting MRD analysis DNA (ctDNA) rapidly evolving clinical study applications and therapeutic interventions. To address these opportunities, BLOODPAC—a multi‐disciplinary consortium representing stakeholders from public, industry, academia, regulatory agencies—formulated lexicon that provides shared framework clear definitions using an emphasis on ctDNA detection. terms in categorized under general MRD, testing methodologies, reporting results, acquisition timepoints, including examples current potential cases tests. overall goal is provide unified language approaches advance technologies, allow data aggregation strengthen future evidence, facilitate approvals, leading as early endpoint trials. We believe common set terminology methods can improve understanding appropriate testing, accelerate development, cancer patients.

Language: Английский

Dealing With the Gene Blues

JCO Oncology Practice, Journal Year: 2024, Volume and Issue: 20(11), P. 1437 - 1440

Published: Nov. 1, 2024

Language: Английский